Afschin Gandjour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Afschin Gandjour has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Christian Apel
Market Access, Health Economics & Political Affairs, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
2 shared publicationsDana Kendzia
Market Access, Health Economics & Political Affairs, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
2 shared publicationsDennis A. Ostwald
SIBE, Graduate School of the Faculty for Leadership and Management, Steinbeis University, Berlin, Germany
2 shared publicationsJovana Petrovic Vorkapic
Market Access, Health Economics & Political Affairs, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
2 shared publicationsUlrich Tschulena
Fresenius Medical Care Deutschland GmbH, Bad Homburg v.d.H., Germany
2 shared publicationsA. Dünkel
1 shared publication
Latest Publications
- Open Access
- 14 September 2026
- Published by Springer Nature in Operations Research Forum
- Vol. 7 (3) , 107
Projected Health Expenditures of Precision Medicine Under a Value-Based Pricing Framework
Precision medicine (PM) has the potential to improve healthcare by tailoring treatments to individual genetic, environmental, and lifestyle factors. However, its high initial costs pose challenges for achieving cost neutrality within healthcare budgets. This study investigates the cost implications of PM through a value-based pricing (VBP) framework. A mathematical model was used to evaluate the economic impact of PM, specifically considering three major cost factors: the optimization of existing therapies through the application of new biomarkers, which can reduce ineffective treatments by better identifying patient subgroups; the development of targeted drugs designed to interact with specific biomarkers, offering higher efficacy but often at premium pricing; and the costs associated with early disease detection and diagnosis, where PM’s emphasis on proactive screening aims to identify conditions at earlier, more treatable stages but introduces additional diagnostic expenditures. The model incorporated drug pricing and market dynamics relevant to the German social health insurance context. Although PM may generate savings under favorable assumptions, the analysis indicates that, in the German base case, the transition to PM is projected to increase annual healthcare costs by approximately €2.6 billion over the next 10 to 20 years. Sensitivity analysis shows substantial uncertainty around this estimate: In the best-case scenario, PM is projected to yield annual net savings of €1.6 billion, whereas in the worst-case scenario total annual PM expenditures rise to €34.7 billion. The findings therefore suggest that the budget impact of PM depends strongly on treatment effectiveness, competition among drug and biomarker producers, and pricing dynamics for new targeted therapies. However, under the current German base case assumptions, PM is not cost neutral and is projected to increase expenditures. Its economic sustainability depends critically on effective competition, pricing discipline for new targeted drugs and biomarkers, and policy measures that support efficient implementation.
- 14 September 2026
- Published by Springer Nature in Operations Research Forum
- Vol. 7 (3) , 107
Open AccessProjected Health Expenditures of Precision Medicine Under a Value-Based Pricing Framework
Precision medicine (PM) has the potential to improve healthcare by tailoring treatments to individual genetic, environmental, and lifestyle factors. However, its high initial costs pose challenges for achieving cost neutrality within healthcare budgets. This study investigates the cost implications of PM through a value-based pricing (VBP) framework. A mathematical model was used to evaluate the economic impact of PM, specifically considering three major cost factors: the optimization of existing therapies through the application of new biomarkers, which can reduce ineffective treatments by better identifying patient subgroups; the development of targeted drugs designed to interact with specific biomarkers, offering higher efficacy but often at premium pricing; and the costs associated with early disease detection and diagnosis, where PM’s emphasis on proactive screening aims to identify conditions at earlier, more treatable stages but introduces additional diagnostic expenditures. The model incorporated drug pricing and market dynamics relevant to the German social health insurance context. Although PM may generate savings under favorable assumptions, the analysis indicates that, in the German base case, the transition to PM is projected to increase annual healthcare costs by approximately €2.6 billion over the next 10 to 20 years. Sensitivity analysis shows substantial uncertainty around this estimate: In the best-case scenario, PM is projected to yield annual net savings of €1.6 billion, whereas in the worst-case scenario total annual PM expenditures rise to €34.7 billion. The findings therefore suggest that the budget impact of PM depends strongly on treatment effectiveness, competition among drug and biomarker producers, and pricing dynamics for new targeted therapies. However, under the current German base case assumptions, PM is not cost neutral and is projected to increase expenditures. Its economic sustainability depends critically on effective competition, pricing discipline for new targeted drugs and biomarkers, and policy measures that support efficient implementation.
- 13 August 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (7) , 815-816
Time, Transfers, and the QALY: Rethinking Leisure and Work in Health-Economic Evaluations
- 13 August 2026
- Published by SAGE Publications in Medical Decision Making
- Vol. 46 (7) , 815-816
Time, Transfers, and the QALY: Rethinking Leisure and Work in Health-Economic Evaluations
- Open Access
- 2 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0350175
Evaluating the impact of the EU Medical Device Regulation (MDR) on mortality and device availability in Germany
Introduction: The EU Medical Device Regulation (MDR), effective since May 25, 2017, aims to enhance the safety and quality of medical devices within the EU. This study models the potential net mortality implications of the MDR in Germany under explicit assumptions about safety improvements, market withdrawals, and certification delays. Methods: A combined top-down and bottom-up approach was employed to evaluate the impact of the EU MDR on mortality in Germany. The top-down approach estimated avoided deaths using the Keyfitz–Vaupel life-table elasticity, while the bottom-up approach quantified mortality reductions attributable to individual MDR-regulated medical devices. Based on the results of both approaches, the analysis also estimated the number of deaths potentially resulting from market withdrawals and certification delays. Results: Official German reports attribute an average of 17 device-related deaths annually, whereas international estimates suggest the true figure may reach up to 2,500 per year. Market withdrawals and certification delays associated with MDR implementation were modelled as potentially contributing an estimated 163–1,884 additional annual deaths and a one-time mortality burden of 700–4,200 deaths. Conclusion: Under central assumptions, the MDR is consistent with long-term reductions in device-related mortality, but transition-period certification bottlenecks and withdrawals—especially for niche/pediatric devices—can offset gains in the short to medium term. Targeted mitigation is warranted to secure benefits and limit unintended harms.
- 2 July 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (7) , e0350175
Open AccessEvaluating the impact of the EU Medical Device Regulation (MDR) on mortality and device availability in Germany
Introduction: The EU Medical Device Regulation (MDR), effective since May 25, 2017, aims to enhance the safety and quality of medical devices within the EU. This study models the potential net mortality implications of the MDR in Germany under explicit assumptions about safety improvements, market withdrawals, and certification delays. Methods: A combined top-down and bottom-up approach was employed to evaluate the impact of the EU MDR on mortality in Germany. The top-down approach estimated avoided deaths using the Keyfitz–Vaupel life-table elasticity, while the bottom-up approach quantified mortality reductions attributable to individual MDR-regulated medical devices. Based on the results of both approaches, the analysis also estimated the number of deaths potentially resulting from market withdrawals and certification delays. Results: Official German reports attribute an average of 17 device-related deaths annually, whereas international estimates suggest the true figure may reach up to 2,500 per year. Market withdrawals and certification delays associated with MDR implementation were modelled as potentially contributing an estimated 163–1,884 additional annual deaths and a one-time mortality burden of 700–4,200 deaths. Conclusion: Under central assumptions, the MDR is consistent with long-term reductions in device-related mortality, but transition-period certification bottlenecks and withdrawals—especially for niche/pediatric devices—can offset gains in the short to medium term. Targeted mitigation is warranted to secure benefits and limit unintended harms.
- Open Access
- 29 June 2026
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 24 (5) , 899-907
The Price of Speed: Estimating the Impact of List Prices on Time to Availability of New Medicines in 18 European Countries
To examine whether higher national list prices for new medicines are associated with faster patient access across 18 European countries. Data were drawn from the 2023 European Federation of Pharmaceutical Industries & Associations (EFPIA) Patients Waiting to Access Innovative Therapies (WAIT) Indicator Survey and the Swedish TLV's 2023 international price index. Time to availability was defined as the number of days between marketing authorisation and national reimbursement access. A multivariable linear regression model was applied, controlling for gross domestic product (GDP) per capita, population size, health technology assessment (HTA) duration, and the use of Managed Entry Agreements (MEAs). To address endogeneity, a two-stage least squares (2SLS) regression was conducted using a composite headquarters (HQ) Index as an instrumental variable for national list prices. In the multivariable model, each one-point increase in the list price index (European average = 100) was associated with a 7.9-day reduction in time to availability (p = 0.091). A slow HTA/reimbursement process was significantly associated with longer delays (p = 0.022). Managed entry agreement intensity was positively associated with longer delays but did not reach statistical significance (p = 0.103). In the 2SLS model, a one-point increase in the instrumented list price was associated with a 14.1-day reduction in access delays in the preferred parsimonious specification (p = 0.011). Sensitivity analyses showed that the negative association was generally preserved across alternative instrumental variable specifications and after exclusion of Poland, although effect sizes and first-stage strength varied. Higher national list prices may be associated with faster patient access to new medicines in European markets. Although the findings are consistent with a possible causal effect, they should be interpreted with caution given the sensitivity of the estimates to specification and sample composition, as well as concerns about instrument validity and strength. The results highlight a potential policy trade-off between affordability and timely availability in pharmaceutical pricing and access frameworks.
- 29 June 2026
- Published by Springer Nature in Applied Health Economics and Health Policy
- Vol. 24 (5) , 899-907
Open AccessThe Price of Speed: Estimating the Impact of List Prices on Time to Availability of New Medicines in 18 European Countries
To examine whether higher national list prices for new medicines are associated with faster patient access across 18 European countries. Data were drawn from the 2023 European Federation of Pharmaceutical Industries & Associations (EFPIA) Patients Waiting to Access Innovative Therapies (WAIT) Indicator Survey and the Swedish TLV's 2023 international price index. Time to availability was defined as the number of days between marketing authorisation and national reimbursement access. A multivariable linear regression model was applied, controlling for gross domestic product (GDP) per capita, population size, health technology assessment (HTA) duration, and the use of Managed Entry Agreements (MEAs). To address endogeneity, a two-stage least squares (2SLS) regression was conducted using a composite headquarters (HQ) Index as an instrumental variable for national list prices. In the multivariable model, each one-point increase in the list price index (European average = 100) was associated with a 7.9-day reduction in time to availability (p = 0.091). A slow HTA/reimbursement process was significantly associated with longer delays (p = 0.022). Managed entry agreement intensity was positively associated with longer delays but did not reach statistical significance (p = 0.103). In the 2SLS model, a one-point increase in the instrumented list price was associated with a 14.1-day reduction in access delays in the preferred parsimonious specification (p = 0.011). Sensitivity analyses showed that the negative association was generally preserved across alternative instrumental variable specifications and after exclusion of Poland, although effect sizes and first-stage strength varied. Higher national list prices may be associated with faster patient access to new medicines in European markets. Although the findings are consistent with a possible causal effect, they should be interpreted with caution given the sensitivity of the estimates to specification and sample composition, as well as concerns about instrument validity and strength. The results highlight a potential policy trade-off between affordability and timely availability in pharmaceutical pricing and access frameworks.
- Open Access
- 19 June 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (11)
Overcoming Access Barriers in European CAR-T Therapy: The Role of Decentralized Manufacturing and the EASYGEN Framework
- 19 June 2026
- Published by Elsevier in Cytotherapy
- Vol. 28 (11)
Open AccessOvercoming Access Barriers in European CAR-T Therapy: The Role of Decentralized Manufacturing and the EASYGEN Framework
- Open Access
- 8 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The cost-effectiveness of inventory reserves for preventing drug shortages in Germany: a health-economic evaluation
Based on a recent legislative change in Germany, maintaining a six-month inventory reserve for pharmaceuticals has become the primary strategy used by the German government to prevent shortages and stockouts. This study aimed to estimate the number of drug shortages preventable under the medicines stockpiling mandate and to determine the maximum stockpiling duration that remains cost-effective. The study adopted the perspective of the German social health insurance and analyzed a publicly available database containing information on all past drug shortages in Germany from the first entry in 2012 to May 2023 (n = 2768). The proportion of preventable drug shortages was estimated as a function of inventory duration. Additionally, secondary data were used to ascertain the costs associated with inventory carrying (including storage, capital, and expiration costs) and the gain in quality-adjusted life years (QALYs) resulting from avoiding relevant shortages of medication packages. Maintaining a six-month inventory could prevent approximately 70% of drug shortages. The empirical analysis revealed a diminishing incremental benefit of extending the drug supply duration, leading to an increasing marginal cost-per-QALY ratio. Based on a health opportunity cost–based cost-effectiveness threshold, the cost-effective upper limit of inventory duration under the current assumptions was approximately 922 days. This estimate was particularly sensitive to assumptions about FIFO (“first in, first out”) warehouse procedures, number of drug shortages, and the valuation of health gains. This study indicates that Germany’s recently introduced six-month inventory mandate could substantially reduce drug shortages and deliver good value for money, with a very high probability of cost-effectiveness across the willingness-to-pay thresholds examined in the sensitivity analysis. However, key uncertainties—especially around FIFO procedure compliance, health opportunity costs, and the clinical consequences of shortages—warrant ongoing monitoring and periodic reassessment as new evidence becomes available.
- 8 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe cost-effectiveness of inventory reserves for preventing drug shortages in Germany: a health-economic evaluation
Based on a recent legislative change in Germany, maintaining a six-month inventory reserve for pharmaceuticals has become the primary strategy used by the German government to prevent shortages and stockouts. This study aimed to estimate the number of drug shortages preventable under the medicines stockpiling mandate and to determine the maximum stockpiling duration that remains cost-effective. The study adopted the perspective of the German social health insurance and analyzed a publicly available database containing information on all past drug shortages in Germany from the first entry in 2012 to May 2023 (n = 2768). The proportion of preventable drug shortages was estimated as a function of inventory duration. Additionally, secondary data were used to ascertain the costs associated with inventory carrying (including storage, capital, and expiration costs) and the gain in quality-adjusted life years (QALYs) resulting from avoiding relevant shortages of medication packages. Maintaining a six-month inventory could prevent approximately 70% of drug shortages. The empirical analysis revealed a diminishing incremental benefit of extending the drug supply duration, leading to an increasing marginal cost-per-QALY ratio. Based on a health opportunity cost–based cost-effectiveness threshold, the cost-effective upper limit of inventory duration under the current assumptions was approximately 922 days. This estimate was particularly sensitive to assumptions about FIFO (“first in, first out”) warehouse procedures, number of drug shortages, and the valuation of health gains. This study indicates that Germany’s recently introduced six-month inventory mandate could substantially reduce drug shortages and deliver good value for money, with a very high probability of cost-effectiveness across the willingness-to-pay thresholds examined in the sensitivity analysis. However, key uncertainties—especially around FIFO procedure compliance, health opportunity costs, and the clinical consequences of shortages—warrant ongoing monitoring and periodic reassessment as new evidence becomes available.
- Open Access
- 18 March 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
Developing shortcut algorithms for value-based pricing of pharmaceuticals
Value-based pricing (VBP) involves regulating the reimbursement or pricing of pharmaceuticals based on their therapeutic value. We adopt VBP as the policy context for this study. Unlike alternative approaches, VBP depends on an explicit relationship between price and incremental health outcomes and costs. This dependence makes VBP decisions especially sensitive to uncertainty about downstream costs and outcomes. A central question is whether—and how far—these components must be modeled beyond the trial period. A key gap is that the literature provides limited, generalizable conditions for when extrapolation is necessary for pricing conclusions versus when trial-period evidence is sufficient. This paper demonstrates the conditions under which it is possible to forgo modeling downstream costs beyond the clinical trial period for VBP purposes. It provides a series of specific mathematical proofs to support this approach. The proposed shortcuts reduce the burden and time required to produce evaluations. Furthermore, the shortcuts validate the robustness of decision models by allowing modelers to test whether applying these assumptions yields consistent results, enhancing the reliability of VBP methodologies.
- 18 March 2026
- Published by Springer Nature in Health Economics Review
- Vol. 16 (1)
Open AccessDeveloping shortcut algorithms for value-based pricing of pharmaceuticals
Value-based pricing (VBP) involves regulating the reimbursement or pricing of pharmaceuticals based on their therapeutic value. We adopt VBP as the policy context for this study. Unlike alternative approaches, VBP depends on an explicit relationship between price and incremental health outcomes and costs. This dependence makes VBP decisions especially sensitive to uncertainty about downstream costs and outcomes. A central question is whether—and how far—these components must be modeled beyond the trial period. A key gap is that the literature provides limited, generalizable conditions for when extrapolation is necessary for pricing conclusions versus when trial-period evidence is sufficient. This paper demonstrates the conditions under which it is possible to forgo modeling downstream costs beyond the clinical trial period for VBP purposes. It provides a series of specific mathematical proofs to support this approach. The proposed shortcuts reduce the burden and time required to produce evaluations. Furthermore, the shortcuts validate the robustness of decision models by allowing modelers to test whether applying these assumptions yields consistent results, enhancing the reliability of VBP methodologies.
- Open Access
- 3 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Health-economic evaluation of a novel personalized digital avatar-based anemia management software in hemodialysis patients
This study aimed to evaluate the cost-effectiveness and financial impact of an anemia management tool (AMT)—a software system that uses real-time blood volume and hemoglobin monitoring data—for adult patients receiving in-center hemodialysis (HD) in the United States. A Markov cohort model was developed to estimate lifetime costs and health outcomes for 1000 in-center HD patients with and without use of AMT. Clinical input parameters, including hemoglobin stability and dose reduction of erythropoiesis-stimulating agents (ESAs), were derived from a randomized controlled trial. The net monetary benefit (NMB) was calculated from the Medicare perspective, while a net financial impact analysis (NFIA) estimated provider-level savings based on ESA dose reductions, Quality Incentive Program (QIP)-related payment adjustments, and implementation costs. From the Medicare perspective, AMT yielded a positive NMB of $8419 per patient over a lifetime and remained cost-effective at a threshold of $2443 per patient per year. The NFIA showed an annual per-patient profit of $218. For a dialysis facility with 70 patients, this corresponds to an annual profit of $15,251. In conclusion, AMT is cost-effective from the Medicare perspective and financially beneficial for providers. Broader adoption may be supported by value-based reimbursement mechanisms and risk-sharing agreements to address residual uncertainties.
- 3 January 2026
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Open AccessHealth-economic evaluation of a novel personalized digital avatar-based anemia management software in hemodialysis patients
This study aimed to evaluate the cost-effectiveness and financial impact of an anemia management tool (AMT)—a software system that uses real-time blood volume and hemoglobin monitoring data—for adult patients receiving in-center hemodialysis (HD) in the United States. A Markov cohort model was developed to estimate lifetime costs and health outcomes for 1000 in-center HD patients with and without use of AMT. Clinical input parameters, including hemoglobin stability and dose reduction of erythropoiesis-stimulating agents (ESAs), were derived from a randomized controlled trial. The net monetary benefit (NMB) was calculated from the Medicare perspective, while a net financial impact analysis (NFIA) estimated provider-level savings based on ESA dose reductions, Quality Incentive Program (QIP)-related payment adjustments, and implementation costs. From the Medicare perspective, AMT yielded a positive NMB of $8419 per patient over a lifetime and remained cost-effective at a threshold of $2443 per patient per year. The NFIA showed an annual per-patient profit of $218. For a dialysis facility with 70 patients, this corresponds to an annual profit of $15,251. In conclusion, AMT is cost-effective from the Medicare perspective and financially beneficial for providers. Broader adoption may be supported by value-based reimbursement mechanisms and risk-sharing agreements to address residual uncertainties.
- Open Access
- 27 December 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 16-28
Annual vaccination with BNT162b2 in Germany can avoid substantial clinical and economic burden of COVID-19 disease
To quantify the clinical and economic burden of Coronavirus disease 19 (COVID-19), and burden potentially avoided with annual vaccination, in German adults in an endemic setting. A decision tree model was constructed to estimate the clinical and economic impact of COVID-19 and projected burden avoided with BNT162b2, a seasonally adapted mRNA vaccine against severe COVID-19 disease. The majority of cost inputs and clinical event probabilities were informed by German real-world evidence from seasons 2022/23 and 2023/24. Vaccine efficacy was derived from US and German studies. Long/Post COVID impact was assessed in scenario analysis. The model estimated up to 20.8 million symptomatic infections per year in adults, including 7.5 million in people aged 60+, and 6.0 million in comorbid adults. This translates to an estimated 198,598 hospitalizations and 24,626 COVID-attributable deaths, with 93.6% of deaths occurring in people aged 60+. The total economic burden including productivity loss was estimated at €1.4 billion in people aged 60+, €2.0 billion in comorbid adults, and €3.9 billion in all working adults. Long/Post COVID increased the economic burden by 1.7 times. Assuming vaccination of 100% of recommended groups, 11.0 million symptomatic infections could be prevented, with the greatest impact in people aged 60+ (estimated 110,362 hospitalizations and 13,685 deaths avoided). For people aged 60+, comorbid adults, and all working adults, the number needed to vaccinate to prevent one symptomatic infection was 7, 4, and 4 people; to prevent one hospitalization, 231, 2,363, and 4,549; and to avoid one death, 1,862, 19,055, and 36,683, respectively. COVID-19 imposes a substantial clinical and economic burden on the German population, which could be mitigated with an expanded COVID-19 vaccination program. Further research into Long/Post COVID is needed. Our study presents considerations highlighting the value of broad vaccination especially for working adults.
- 27 December 2025
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 16-28
Open AccessAnnual vaccination with BNT162b2 in Germany can avoid substantial clinical and economic burden of COVID-19 disease
To quantify the clinical and economic burden of Coronavirus disease 19 (COVID-19), and burden potentially avoided with annual vaccination, in German adults in an endemic setting. A decision tree model was constructed to estimate the clinical and economic impact of COVID-19 and projected burden avoided with BNT162b2, a seasonally adapted mRNA vaccine against severe COVID-19 disease. The majority of cost inputs and clinical event probabilities were informed by German real-world evidence from seasons 2022/23 and 2023/24. Vaccine efficacy was derived from US and German studies. Long/Post COVID impact was assessed in scenario analysis. The model estimated up to 20.8 million symptomatic infections per year in adults, including 7.5 million in people aged 60+, and 6.0 million in comorbid adults. This translates to an estimated 198,598 hospitalizations and 24,626 COVID-attributable deaths, with 93.6% of deaths occurring in people aged 60+. The total economic burden including productivity loss was estimated at €1.4 billion in people aged 60+, €2.0 billion in comorbid adults, and €3.9 billion in all working adults. Long/Post COVID increased the economic burden by 1.7 times. Assuming vaccination of 100% of recommended groups, 11.0 million symptomatic infections could be prevented, with the greatest impact in people aged 60+ (estimated 110,362 hospitalizations and 13,685 deaths avoided). For people aged 60+, comorbid adults, and all working adults, the number needed to vaccinate to prevent one symptomatic infection was 7, 4, and 4 people; to prevent one hospitalization, 231, 2,363, and 4,549; and to avoid one death, 1,862, 19,055, and 36,683, respectively. COVID-19 imposes a substantial clinical and economic burden on the German population, which could be mitigated with an expanded COVID-19 vaccination program. Further research into Long/Post COVID is needed. Our study presents considerations highlighting the value of broad vaccination especially for working adults.
- 15 October 2025
- Published by Elsevier in Value in Health
Health-Economic Evaluation of COVID-19 Updated Booster Vaccination and Age-Related Cost Outcomes
- 15 October 2025
- Published by Elsevier in Value in Health
Health-Economic Evaluation of COVID-19 Updated Booster Vaccination and Age-Related Cost Outcomes